Expert Q&A: Do weight-loss drugs cause pancreatitis?

Expert Q&A: Do weight-loss drugs cause pancreatitis?

Share on Pinterest
Weight loss jabs may come with a small risk of acute pancreatitis. But how concerned should people be? Image credit: Varlay/Getty Images
  • GLP-1 receptor agonists, a class of medication used to treat type 2 diabetes and obesity, are sold under many brand names, including Wegovy, Ozempic, and Mounjaro.
  • Although rare, these injections have been linked to a few side effects, including acute pancreatitis, or the inflammation of the pancreas.
  • Following a recent rise in such reports, the U.K. has updated its guidance on weight-loss injections.
  • Experts agree that this should not be a cause for alarm, but that people should be informed about this risk and the signs of pancreatitis to look out for.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro, which are used to treat type 2 diabetes and obesity, have been growing in popularity — so much so that in December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss.

However, as life changing as these medications have been for some people, they have also been linked to a few serious but rare side effects. One of these effects, which has come under scrutiny recently, has been acute pancreatitis.

The latest body to take action on this is the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, which recently updated its guidance on these weight loss jabs, citing a rise in cases of acute pancreatitis reported to the Yellow Card scheme, which monitors adverse reactions to medications.

Acute pancreatitis is the inflammation of the pancreas, presenting with symptoms such as sudden abdominal pain, nausea, and swelling. The patient information leaflets for drugs such as Wegovy, Ozempic, and Mounjaro state that pancreatitis is an “uncommon” side effect, affecting about one in 100 patients.

Data shows that 1.6 million adults in England, Wales, and Scotland used a GLP-1 medication for weight loss between 2024 and 2025.

In the U.K., between 2007 and October 2025, 1,296 yellow card reports of pancreatitis linked to GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists were reported, of which 19 were fatal.

Medical News Today spoke to three medical experts — Hector Perez, MD, a board-certified bariatric surgeon at Renew Bariatrics and an advisor at BestSurgeons, Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, and David Cutler, MD, a board-certified family medicine physician at Providence Saint John’s Health Center in Santa Monica, CA — about weight loss injections, their side effects, and how to spot signs of acute pancreatitis.

Team Health Accessible
Author

Team Health Accessible

Health & Wellness Editorial Team

HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.

Leave a Reply

Your email address will not be published. Required fields are marked *

Share